Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PILOT: Perioperative Tislelizumab + Chemotherapy in ESCC
NCT06056336Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Disease-Free Survival at 2 years. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06056336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056336.